bioAffinity Technologies, Inc. — Regulatory Filings 2026

May 8, 2026

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2026

BIOAFFINITY TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41463	46-5211056
(State
or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S.
Employer Identification Number)

3300 Nacogdoches Road , Suite 216

San Antonio , Texas 78217

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $.007 per share | BIAF | The
Nasdaq Stock Market LLC |
| Tradeable
Warrants to purchase Common Stock | BIAFW | The
Nasdaq Stock Market LLC |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 2.02. Results of Operation and Financial Condition.

On May 8, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for its first quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this Current Report on Form 8-K:

Exhibit	Description
99.1	Press Release issued by bioAffinity Technologies, Inc. dated May 8, 2026
104	Cover
Page Interactive Data File (embedded within the Inline XBRL document)

Field: Page; Sequence: 2; Options: NewSection; Value: 2

• 2 -

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

| Date:
May 8, 2026 | |
| --- | --- |
| By: | /s/
Maria Zannes |
| Name: | Maria
Zannes |
| Title: | President
and Chief Executive Officer |

Field: Page; Sequence: 3; Options: Last

• 3 -

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kUFuwjAQRU/AHUZRlwicVICUXRtRVBWqCCLa7ZAMJSLxRGOHwpF6yzoJaVm0liXLnv/+n5E9b+gt+CkvSOD9cb2EhMqqQEuwpj0J6ZScInp+CcGda/rIjRXUtr32YMSOIcdMRxN0763ylBvKQlCTsZqNgymo+1D5EK+8QVOPWO/zjLTNsQDUGcTCleRkUS6dQ4Jn1lxe2qQticlZh+CPVFf+gkD5AbzyCT9ZjgaWy8gbDNs18BbCdeVU87Ml3ZAwL6h0caajf3fbTVoby2WYCGaEu4LeUJohTcJxLekBDbkRS9Yby+lxReWOxFG+CgJfPVwb+oGhp8EyVFceOgNoHf6IvvGPUbZY1DRSahaTbA4o9E/mrekQKhQ4NSTcNSxU7mtMQ/d532aVlZA=